First human trial launches: can boosting the Brain's immune system fight Alzheimer's?
NCT ID NCT05606341
Summary
This is an early safety study testing a new drug designed to stimulate the body's natural immune defenses in people with early Alzheimer's disease or mild cognitive impairment. The trial will enroll 39 participants to receive either the drug or a placebo at different dose levels over 8 weeks. The main goal is to see if the treatment is safe and well-tolerated, while also checking for any early signs of effect on thinking skills and Alzheimer's-related proteins.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.